Open-label Pilot Study Synbiotic Treatment for Autism Spectrum Disorder

Summary

The objective of this study is to conduct a open-label pilot study evaluating the feasibility, tolerability and preliminary efficacy of a 12-week course of synbiotic in improving anxiety symptoms in children with ASD. The investigators hypothesise that the course of synbiotic will feasible and tolerable, and that there will be a reduction in anxiety symptoms in ASD children after the 12-week course of synbiotic.

Eligibility

Inclusion Criteria:

1. ASD children of Chinese ethnicity aged \<12 with diagnosis made by child psychiatrists based on Diagnostic and Statistical Manual, Fifth Edition (DSM-5) diagnostic criteria.
2. Elevated anxiety level, as measured by Anxiety Scale for Children-Autism Spectrum Disorder (ASC-ASD)
3. Presence of sensory hyperresponsiveness, as measured by Sensory Experience Questionnaire (SEQ)

Exclusion Criteria:

1. Co-occurring mental retardation, neurological, psychosis, depression or other severe mental illness.
2. History of non-functional gastrointestinal disorders such as inflammatory bowel disease and Hirschsprung's disease.
3. Presence of other significant physical illness, including but not limited to: current active malignancy, immunosuppression, organ failure and epilepsy
4. Exposure to antibiotics within 1 months of the study or history of using probiotics.
5. On special diet such as being a vegetarian

Conditions2

Browse More Trials